Sheba ARC: The Global Innovation Arm and Sheba Medical Center's International Position
Sheba Medical Center's ARC (Accelerate, Redesign, Collaborate) Innovation Center operates as a major hospital-based innovation arm coordinating clinical research, AI deployment, medical-device evaluation, and international partnerships. Inside ARC, Sheba's international ranking, and the broader Israeli hospital-innovation architecture.
Sheba Medical Center (Tel HaShomer), Israel's largest hospital and one of the country's leading clinical institutions, operates the ARC (Accelerate, Redesign, Collaborate) Innovation Center as the hospital's flagship innovation arm.
ARC coordinates clinical research, AI deployment within clinical practice, medical-device evaluation, international academic and commercial partnerships, and the broader Sheba institutional commitment to operating as a leading global hospital innovation platform.
Sheba's institutional position
Sheba Medical Center, founded in 1948 in the months following Israeli independence, operates as one of the major Israeli hospitals. Per institutional materials, Sheba has been recognized by Newsweek among the world's top hospitals across multiple recent annual rankings — a positioning that has anchored the hospital's international visibility alongside its substantial clinical, research, and teaching mandates.
The institutional scope includes:
— Substantial inpatient and outpatient clinical capacity across all major medical specialties — Affiliation with the Sackler Faculty of Medicine at Tel Aviv University as a primary teaching hospital — Major research output across clinical and translational medicine — Substantial international patient flows, particularly from the broader Middle East, Russia and CIS, and the wider international patient base
The ARC Innovation Center
ARC operates as Sheba's structured innovation arm, coordinating multiple categories of activity:
Clinical AI deployment. ARC has positioned Sheba as one of the leading global hospital deployments of clinical-decision-support AI across radiology, pathology, oncology, and adjacent specialties. The hospital has partnered with multiple Israeli and international AI operators on production deployment in operational clinical environments.
Medical-device evaluation and partnerships. ARC operates as one of the major hospital-side institutional partners for Israeli medical-device startups, providing the clinical evaluation environment, the partnership architecture, and the operational deployment context that medical-device commercialization requires.
International partnerships. Sheba has expanded international partnership architecture substantially through 2018-2026, with affiliations and collaboration agreements spanning multiple geographies. Per institutional disclosures, several Gulf state, European, and Asian institutions have entered formal collaboration agreements with Sheba covering specific clinical, research, and operational programs.
Clinical research. Sheba operates a substantial clinical-research portfolio, including major studies in pandemic-era infectious disease (the institution was one of the global leaders in COVID-19 vaccine clinical evaluation), oncology, cardiology, and broader research areas.
The international position
Sheba's international position operates across several dimensions.
Patient flows. International patient flows from the broader Middle East (covered at /health/gcc-medical-tourism/), Russia and CIS, and the wider international patient base produce substantial patient volume. Specific patient-flow figures are disclosed in periodic institutional materials.
Academic partnerships. Sheba operates partnership arrangements with major US, UK, European, and Asian academic medical centers covering specific clinical, research, and educational programs.
Commercial collaborations. Sheba operates substantial commercial partnership activity with Israeli and international medical-device, biotech, AI, and pharmaceutical operators.
The broader Israeli hospital-innovation architecture
Sheba operates alongside several other major Israeli hospitals with substantial innovation activity:
— Hadassah Medical Organization (Hadassah-Ein Kerem, Hadassah-Mount Scopus) — covered separately, operates substantial research and clinical innovation — Rambam Health Care Campus (Haifa) — major northern Israeli academic medical center — Tel Aviv Sourasky Medical Center (Ichilov) — central Tel Aviv academic medical center — Shaare Zedek Medical Center (Jerusalem) — substantial Jerusalem clinical institution — Rabin Medical Center (Beilinson, Hasharon) — major hospital complex
Each operates institutional innovation activity at meaningful scale; Sheba's ARC structure is the most extensively branded and externally visible of the Israeli hospital innovation arms.
The technology transfer architecture
Hospital-based research commercialization operates substantially through technology transfer companies. The major Israeli academic medical centers each operate technology transfer organizations: Yeda (Weizmann), Yissum (Hebrew University), Ramot (Tel Aviv University), and the broader university and hospital technology transfer tier.
The technology transfer architecture interfaces with the Israeli VC and growth-equity sector (covered in The Olam's Venture cluster) and produces ongoing pipeline of medical-device, biotech, AI, and health-services operators.
What 2026-2027 looks like
Sheba's continued international expansion, ARC's continued operational scope, and the broader Israeli hospital-innovation architecture all support continued operational expansion through 2026-2027.
The post-October 7 environment did not produce structural disengagement of major international partnerships; institutional commitments through 2024-2026 reflect continued operating partnerships across multiple geographies.
Source data: Sheba Medical Center public materials; ARC Innovation Center public materials; Newsweek World's Best Hospitals annual rankings; coverage in Times of Israel, Globes, Calcalist, JNS, eJewishPhilanthropy. Data current as of Q2 2026.